Refeyn, the company behind pioneering mass photometry technologies, has taken another step to assure mass photometry is a simpler, more efficient bioanalytics tool with the release of a powerful ...

Automated mass photometry combines the unparalleled simplicity and sensitivity of Refeyn’s molecular mass measurement technology with the efficiency and ease of automation. This approach offers ...

Refeyn has announced that mass photometry has been recognized by the US Pharmacopeia (USP) – and referenced in the new draft USP general chapter <1067> – as a key orthogonal method for characterizing ...

Refeyn, the company behind pioneering mass photometry technology, has been named in The Sunday Times 100 Tech 2026, an annual ranking of the fastest-growing private technology companies in the UK. The ...

A recently-developed technique for measuring the mass of single molecules in solution has the potential to help companies using adeno-associated viruses (AAV) as a vector for gene therapies. That’s ...

A UK bioanalytical technology company has been ranked among the fastest-growing private tech firms, reflecting strong revenue growth and rising adoption of mass photometry tools across academia, ...

mRNA technologies have rapidly evolved into one of the most exciting and versatile classes of modern medicines, powering breakthroughs in vaccines and emerging therapies for metabolic, cardiovascular, ...

The US Pharmacopeia (USP) has recognized mass photometry as a key orthogonal method for characterizing its new adeno-associated virus (AAV) reference standards, as referenced in the draft general ...